FibroGen Inc (FGEN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
November 2018
36
About the Report
About the Report
Summary
FibroGen Inc (FibroGen) is a biotechnology company that discovers, develops and commercializes new therapeutics. The company's pipeline product portfolio includes FG-4592, an oral small molecule inhibitor of HIF prolyl hydroxylases that is used for the treatment of anemia in chronic kidney disease; FG-3019, a monoclonal antibody developed to treat duchenne muscular dystrophy, idiopathic pulmonary fibrosis, pancreatic cancer, and liver fibrosis. Its roxadustat is supported by extensive clinical data demonstrating correction and maintenance of hemoglobin levels in multiple subpopulations of CKD anemia patients. The company conducts research and development in the fields of connective tissue growth factor and hypoxia-inducible factor. FibroGen is headquartered in San Francisco, California, the US.
FibroGen Inc (FGEN)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.
- Business Description-A brief description of the company's operations.
- Key Employees-A list of the key executives of the company.
- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors-A list of the key competitors of the company.
- Key Recent Developments-A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Products
Products
FibroGen Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.
Table of Contents
Table of Contents
Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
FibroGen Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
FibroGen Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
FibroGen Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
FibroGen Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
FibroGen Inc, Medical Devices Deals, 2012 to YTD 2018 9
FibroGen Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
FibroGen Inc, Pharmaceuticals & Healthcare, Deal Details 11
Partnerships 11
AstraZeneca Enters Into Co-Development Agreement With FibroGen For FG-4592 11
Equity Offering 12
FibroGen Raises USD374.9 Million in Public Offering of Shares 12
FibroGen Raises USD120 Million in Public Offering of Shares 13
FibroGen Raises USD168 Million in IPO of Shares 15
FibroGen to Raise USD20 Million in Private Placement of Shares 17
FibroGen Inc-Key Competitors 19
FibroGen Inc-Key Employees 20
FibroGen Inc-Locations And Subsidiaries 21
Head Office 21
Other Locations & Subsidiaries 21
Recent Developments 22
Financial Announcements 22
Aug 07, 2018: FibroGen reports second quarter 2018 financial results 22
May 09, 2018: FibroGen Reports First Quarter 2018 Financial Results 23
Feb 27, 2018: FibroGen Announces Fourth Quarter and Full Year 2017 Financial Results 25
Nov 08, 2017: FibroGen Reports Third Quarter 2017 Financial Results 26
Aug 07, 2017: FibroGen Reports Second Quarter 2017 Financial Results 28
May 09, 2017: FibroGen Reports First Quarter 2017 Financial Results 29
Mar 01, 2017: FibroGen Reports Fiscal 2016 Financial Results 30
Corporate Communications 31
Sep 19, 2017: FibroGen Appoints Gerald Lema to Board of Directors 31
Product News 32
03/31/2017: FibroGen Announces China FDA Approval of CTA to Conduct Pivotal Phase 2/3 Clinical Trial of Roxadustat in Anemia Associated With Lower Risk MDS 32
Clinical Trials 33
Mar 30, 2017: Positive Results Published in Nephrology Dialysis Transplantation From Two China Phase 2 Trials of Roxadustat for Treatment of Anemia in Chronic Kidney Disease 33
Jan 30, 2017: FibroGens Roxadustat (FG-4592) Meets Primary Endpoints in Two Phase 3 Anemia Studies in China 34
Appendix 36
Methodology 36
About GlobalData 36
Contact Us 36
Disclaimer 36
List of Figure
List of Figures
FibroGen Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
FibroGen Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
FibroGen Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
FibroGen Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
FibroGen Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
FibroGen Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
FibroGen Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
FibroGen Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
FibroGen Inc, Medical Devices Deals, 2012 to YTD 2018 9
List of Table
List of Tables
FibroGen Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
FibroGen Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
FibroGen Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
FibroGen Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
FibroGen Inc, Deals By Therapy Area, 2012 to YTD 2018 8
FibroGen Inc, Medical Devices Deals, 2012 to YTD 2018 9
FibroGen Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
AstraZeneca Enters Into Co-Development Agreement With FibroGen For FG-4592 11
FibroGen Raises USD374.9 Million in Public Offering of Shares 12
FibroGen Raises USD120 Million in Public Offering of Shares 13
FibroGen Raises USD168 Million in IPO of Shares 15
FibroGen to Raise USD20 Million in Private Placement of Shares 17
FibroGen Inc, Key Competitors 19
FibroGen Inc, Key Employees 20
FibroGen Inc, Subsidiaries 21
Why Buy From US?
What makes us stand out is that our consultants follows Robust, Refine and Result (RRR) methodology. i.e. Robust for clear definitions, approaches and sanity checking, Refine for differentiating respondents facts and opinions and Result for presenting data with story
We have set a benchmark in the industry by offering our clients with syndicated and customized market research reports featuring coverage of entire market as well as meticulous research and analyst insights.
While we don't replace traditional research, we flip the method upside down. Our dual approach of Top Bottom & Bottom Top ensures quality deliverable by not just verifying company fundamentals but also looking at the sector and macroeconomic factors.
With one step in the future, our research team constantly tries to show you the bigger picture. We help with some of the tough questions you may encounter along the way: How is the industry positioned? Best marketing channel? KPI's of competitors? By aligning every element, we help maximize success.
Our report gives you instant access to the answers and sources that other companies might choose to hide. We elaborate each steps of research methodology we have used and showcase you the sample size to earn your trust.
If you need any support, we are here! We pride ourselves on universe strength, data quality, and quick, friendly, and professional service.